ImmunityBio (IBRX) said Tuesday it has secured $100 million in financing transactions, including $75 million in non-dilutive funding from Oberland Capital.

The non-dilutive funding increases total committed capital under its existing royalty interest purchase agreement to $375 million, the company said.

Additionally, ImmunityBio said Nant Capital, an entity affiliated with its executive chairman, converted $25 million of outstanding debt to 4.6 million shares, reducing debt under a $505 million promissory note issued in December 2024.

Proceeds will support global expansion following recent approvals and advance its broader immunotherapy pipeline, ImmunityBio said.

Shares of ImmunityBio were 6% higher in Tuesday premarket trading.